hat
Letrozol se yon anti-estwojèn nan fanmi an Inhibitor (AI) Aromatase ak se youn nan ki pi potansyèl ak pwisan efikas nan tout AI a. An reyalite, puisans li yo se pafwa twòp pou kèk nan okipe lè yo itilize pou itilize etikèt sou. Letrozole premye te vin US FDA apwobasyon nan lane 1997 e li ta frape mache a anba non Femara nan mak nan Novartis. Malgre ke Femara se non an komès domine nan AI a, kontrèman ak pi AI a li se youn nan sèlman jeneralman li te ye pa Letrozole pwodui chimik non li byen lwen pi souvan pase non domine li yo domine.
eng
Letrozole is an anti-estrogen of the Aromatase Inhibitor (AI) family and is one of the most potent and powerfully effective of all AI’s. In fact, its potency is sometimes too much for some to handle when used for off label use. Letrozole first gained U.S. FDA approval in 1997 and would hit the market under the brand name Femara through Novartis. Although Femara is the dominating trade name of the AI, unlike most AI’s it is the only one generally known by its chemical name Letrozole far more commonly than its dominating brand name.